Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.36 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | GGT1 | P19440 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270706 | 0.83 | NAALAD2 (0.38) | CYP1A2CYP3A4RECQLNAALAD2GGT1 | |
| SCHEMBL18843220 | 0.76 | CYP1A2 (0.41) | CYP1A2CYP3A4RECQLMAPK1NAALAD2 | |
| SCHEMBL1687263 | 0.75 | — | — | |
| SCHEMBL28098099 | 0.75 | TSHR (0.38) | NAALAD2GGT1TSHRALDH1A1KDM4C | |
| SCHEMBL28098101 | 0.75 | TSHR (0.38) | NAALAD2GGT1TSHRALDH1A1KDM4C | |
| SCHEMBL2235123 | 0.73 | ALDH1A1 (0.36) | CYP1A2CYP3A4MAPK1NAALAD2GGT1 | |
| Hydrochloric Acid SCHEMBL10648828 | 0.73 | MAPK1 (0.44) | CYP1A2CYP3A4RECQLMAPK1KDM4E | |
| SCHEMBL27735475 | 0.72 | CYP1A2 (0.39) | CYP1A2CYP3A4RECQLMAPK1 | |
| SCHEMBL27735477 | 0.72 | CYP1A2 (0.39) | CYP1A2CYP3A4RECQLMAPK1 | |
| SCHEMBL22617691 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| EP-1577323-B1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8361968-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120015868-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20090318365-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090298765-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-03 | — | — | US | disclosed |
| US-7625869-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-01 | — | — | US | disclosed |
| EP-2113513-A2 | Metastin derivatives and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20060241051-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | disclosed |
| EP-1577323-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015868-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | CYP1A2 4794/4885CYP3A4 4493/4885RECQL 4678/4885 |
| US-20090318365-A1 | METASTIN DERIVATIVES AND USE THEREOF | MET, HGF, HGFAC | CYP1A2 4775/4885CYP3A4 4385/4885RECQL 4661/4885 |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | GNRHR, SHBG, MEN1 | CYP1A2 4601/4885CYP3A4 4495/4885RECQL 4480/4885 |
| US-20060241051-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | CYP1A2 4794/4885CYP3A4 4493/4885RECQL 4678/4885 |
| US-20090298765-A1 | Metastin derivatives and use thereof | GNRHR, SHBG, MEN1 | CYP1A2 4601/4885CYP3A4 4495/4885RECQL 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.